Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480039 | 0.84 | CYP4F2 (0.41) | CYP4F2CYP4A11NPSR1CYP3A4CYP2C19 | |
| SCHEMBL2633807 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL2633876 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL8278881 | 0.77 | CYP4F2 (0.71) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL17725098 | 0.77 | CYP4F2 (0.47) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL6629252 | 0.77 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL6627868 | 0.77 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL7271169 | 0.76 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL14857995 | 0.76 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL12555124 | 0.76 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1P2RX7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9533995-B2 | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof | SANOFI (FR) | 2017-01-03 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059863-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059863-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143163-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143163-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315923-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | CYP4F2 557/4885CYP4A11 177/4885NPSR1 3/4885 |
| US-20130059863-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | CHRM2, NR3C2, NPSR1 | CYP4F2 557/4885CYP4A11 177/4885NPSR1 3/4885 |
| US-20130059874-A1 | SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NPSR1, NPR1 | CYP4F2 1788/4885CYP4A11 733/4885NPSR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.